News

FDA commissioner stirs debate over hormone therapy for menopause
A Food and Drug Administration expert panel has reignited a debate over whether hormone therapy should be used to treat ...
The FDA May Finally Remove The Black Box Warning On Hormone Therapy Products. Here’s When It Might Happen
Hormone therapy has endured a rather bumpy history after the Women’s Health Initiative published clinical trial data in 2002 ...
FDA panel to revisit menopausal hormone therapy
MENOPAUSAL THERAPY IN FOCUS — The FDA will hold a panel discussion Thursday on hormone therapy for menopausal women, a pet ...
BizPac Review2d
‘All of us are begging’: New push for FDA to remove ‘black box’ warnings from menopause products
The debate over whether to use hormone therapy to treat menopausal women continues, as a Food and Drug Administration (FDA) expert panel weighs in. The panel, consisting […] ...
Managed Healthcare Executive7d
FDA Panel Challenges Hormone Replacement Therapy Risks
A panel of 12 experts in the menopause field reexamined the findings of the 2002 Women’s Health Initiative study that said ...
BioPharma Dive6d
Panel urges FDA to remove warnings on hormonal menopause therapy
A meeting held by the FDA Thursday spotlighted debate over black box warnings that have limited use of hormone treatment for ...
Flow Space on MSN7d
FDA Experts Call for Rethink on Menopause Hormone Therapy Warnings
On Thursday in Washington, D.C., the U.S. Food and Drug Administration (FDA) convened a panel of top experts to reassess the ...
FiercePharma1y
Another delay for Ascendis' hormone therapy as FDA extends review by 3 ...
It’s been a long wait for Ascendis Pharma to score FDA approval for its hormone replacement therapy TransCon PTH (palopegteriparatide). And, now, it’ll take another three months for the U.S ...
Becker's Hospital Review7y
FDA OKs hormone therapy for vaginal condition tied to menopause: 4 ...
The FDA approved TherapeuticsMD’s hormone therapy Imvexxy for a vaginal condition linked to low estrogen levels during menopause, the company announced May 30. 1. Imvexxy is intended to treat ...
Reuters1y
US FDA extends review of Ascendis Pharma's hormone disorder therapy
The U.S. Food & Drug Administration has extended its review of Ascendis Pharma's therapy to treat adult patients with a hormone disorder by three months, the company said on Tuesday.
Axios on MSN7d
FDA panel backs menopausal hormone therapy
An Food and Drug Administration expert panel on Thursday endorsed removing the "black box" warning on hormone treatments for ...
AOL1y
US FDA extends review of Ascendis Pharma's hormone disorder therapy - AOL
(Reuters) -The U.S. Food & Drug Administration has extended its review of Ascendis Pharma's therapy to treat adult patients with a hormone disorder by three months, the company said on Tuesday. U ...